PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
WEBAug 16, 2024 | Webinars. With the flu season rapidly approaching, there is a surge in influenza and vaccine-related studies. These studies often face the significant challenge of a very short recruitment window, which necessitates thorough preparation and strategic planning during the design phase. Addressing these challenges early is crucial ...
PME - PMLiVE
WEBPharmaceutical Market Europe – October 2023. Launch excellence – adapting to data disruption; preparing for the clinical trials of the future; the impact of cell therapies on cancer treatments.
AstraZeneca/Moderna’s mRNA treatment for heart failure looks …
WEBNov 17, 2021 · The therapy – an mRNA-encoding vascular endothelial growth factor – looks promising for patients undergoing coronary artery bypass surgery. After eight years of collaboration on mRNA-based therapeutics, AstraZeneca and Moderna have announced promising, early results for their candidate therapy AZD8601. In …
PME - Home
WEBHow AI and digital innovations can help agencies and pharma support HCPs in the fight against COVID-19 - PME Supplement August 2020. As the realities of COVID-19 hit and lockdown restrictions came into force around the world, agencies and pharma suddenly found themselves embracing AI and digital innovations at an accelerated rate.
Moderna seeks full FDA approval for its COVID-19 vaccine
WEBJun 2, 2021 · Moderna is seeking a full US Food and Drug Administration (FDA) approval for its COVID-19 vaccine mRNA-1273, after gaining an emergency use authorisation (EUA) for the jab late last year.
PME - Articles - Pharmaceutical Market Europe
WEBNews - July/Aug 2024. Roche and Ascidian agree to $1.8bn neurological disease partnership. 15 July 2024 News & Columns. Read More. Dermatology news - July/Aug 2024. UCB’s Bimzelx approved by MHRA for hidradenitis suppurativa. 15 July 2024 News & Columns. Read More. DARWIN'S MEDICINE - Bayer's octopus move.
Healthcare Archives - PMLiVE
WEBJCVI announces advice for autumn COVID-19 vaccination programme eligibility. Aug 6, 2024 | News, Healthcare. The Committee has advised offering the vaccine to those at high risk of serious disease. Read More.
Merck/Daiichi Sankyo’s ADC candidate shows promise in phase 3 …
WEB4 days ago · EGFR-activating mutations occur in up to 38% of all NSCLC tumours globally. Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC) met its primary endpoint of progression-free survival (PFS). The phase 3 HERTHENA-Lung02 ...
Communique - PMLiVE
WEBCommuniqué – Volume 53. New insights in health comms innovation. Communiqué Awards 2022 – winners’ case studies. INSIGHTS – Demonstrating impact • Driving behaviour change.
Allergan pushes on with Botox for depression - PMLiVE
WEBApr 7, 2017 · Allergan pushes on with Botox for depression. Allergan has reported mixed top-line data from a mid-stage trial of its wrinkle treatment Botox in patients with major depressive disorder (MDD), but still thinks it is worth testing the drug in phase III. The specialty pharma group took the decision to test Botox in depression after external ...
Skip to content